Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt, +23

The Lancet

GastroenterologyTight Control ManagementClinical GastroenterologyUlcerative ColitisMedicine +1

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese, Séverine Vermeire, Wen Zhou, +20

The Lancet

Anti-inflammatorySystemic TreatmentGastroenterologyClinical TrialsMaintenance Therapy +5

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

Milton Packer, Wilson S. Colucci, Lloyd D. Fisher, +10

JACC Heart Failure

Heart FailureCardiogenic ShockCardiovascular DiseaseShort-term Clinical CoursePharmacotherapy +5

Cardiovascular Safety of Testosterone-Replacement Therapy

A. Michael Lincoff, Shalender Bhasin, Panagiotis Flevaris, +22

New England Journal of Medicine

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert, +28

The Lancet

RheumatologyInduction TherapyImmunologyGastroenterologyClinical Trials +7

Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs

David Y. Graham, Naurang M. Agrawal, Donald R. Campbell, +4

Archives of Internal Medicine

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

William J. Sandborn, Brian G. Feagan, Edward V. Loftus, +19

Gastroenterology

Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children

Jeffrey S. Hyams, Anne M. Griffiths, James Markowitz, +11

Gastroenterology

Severe CrohnAutoimmune DiseaseGastroenterologyPediatricsPediatric Gastroenterology +2

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert, +28

The Lancet

Fortify Maintenance TrialRheumatologyWithdrawal Phase 3GastroenterologyTreatment Option +5

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

William J. Sandborn, Subrata Ghosh, Julián Panés, +9

Gastroenterology